Psoriasis, a chronic inflammatory skin disease, relies heavily on abnormal angiogenesis for its pathogenesis, and AlkB ...
Variational AI’s Enki™ generative AI platform designed novel ATR/mTOR dual inhibitors with brain penetrance and activity in ...
For more details about SABCS please visit: https://www.sabcs.org/.
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its ...
Komal Jhaveri - Breast Medical Oncologist and Early Drug Development Specialist, Memorial Sloan Kettering Cancer Center, New York, ...
Exerkines, the molecular signals released through physical exertion, may be protective against radiation toxicities for patients with prostate cancer.
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion ...
(Z)-Endoxifen is Atossa's investigational ER-modulating small molecule. In oncology and CNS studies to date, (Z)-endoxifen has shown a favorable safety profile and pharmacology distinct from tamoxifen ...
Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a ...
Rakovina Therapeutics Inc., a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, has announced impressive results from its AI-enabled ATR program at the recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback